Name: Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico de ASA404 en combinación con Paclitaxel y carboplatin como tratamiento de primera línea para el cáncer de pulmón de células no pequeñas (CPCNP) localmente avanzado o metastásico (estadio IIIb/IV)
Published: 2026-03-15T21:50:48.566Z

El propósito de este estudio es determinar si la adición de ASA404 a la quimioterapia estándar hace que el tratamiento del cáncer sea más eficaz en pacientes con cáncer de pulmón avanzado.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Histologically confirmed non-small cell carcinoma of the lung. (Histological or cytological specimens must be collected via surgical biopsy, brushing, washing or core needle aspiration of a defined lesion. Sputum cytology is not acceptable.)
Newly diagnosed Stage IIIb disease (malignant pleural effusion or pericardial effusion that have been confirmed cytologically) or Stage IV disease
No prior systemic antineoplastic treatment for Stage IIIb/IV non-small cell carcinoma of the lung (Prior neoadjuvant or adjuvant chemotherapy for earlier stage I/II NSCLC is allowed if 12 months or more prior to Baseline visit.)
Age ≥ 18 years old
WHO Performance Status of 0-1
Measurable or non-measurable disease per RECIST criteria (Post-text supplement 1)
Lab values within the range, as defined below, within 2 weeks of randomization:
Absolute neutrophils count (ANC) \> 2.0 x 109/L
Platelets ≥ 100 x109/L
Hemoglobin ≥ 10 g/dL
Serum creatinine ≤ 1.5 x ULN (≤ 120 micro mol/L)
Serum bilirubin ≤ 1.5 x ULN (≤ 25 micro mol/L)
Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases)
International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 x IULN (Sections 6.9.1 and 7.3.4.2)
Electrolyte values (potassium, calcium, magnesium) within \> 1 x LLN and \< 1 x ULN. Patients with corrected electrolyte values are eligible. See Sections 6.8.1 and 7.3.4.3.
Females of child-bearing potential must have negative serum pregnancy test (confirmation of negative urine pregnancy test within 72 hours prior to initial dosing).
Life expectancy ≥ 12 weeks
Written informed consent obtained according to local guidelines

Criterios de exclusión

Patients having CNS metastases (Patients having any clinical signs of CNS metastases must have a CT or MRI of the brain performed to rule out CNS metastases in order to be eligible for study participation. Patients who have had brain metastases surgically removed or irradiated with no residual disease confirmed by imaging are allowed.).
Patients with a history of another primary malignancy ≤ 5 years, with the exception of non-melanoma skin cancer or cervical cancer in situ.
Radiotherapy ≤ 2 weeks prior to randomization. Patients must have recovered from all radiotherapy-related toxicities.
Concurrent use of other investigational agents and patients who have received investigational agents ≤ 4 weeks prior to randomization
Prior exposure to Tumor-VDAs or other vascular targeting agents (anti-VEGF, anti-VEGF receptor agents, anti-EGFR agents \[bevacizumab, cetuximab, etc.\])
Pleural effusion that causes ≥ CTC grade 2 dyspnea
Patients with systolic BP \> 160 mm Hg and/or diastolic BP \>90 mm Hg
Patients with recent hemoptysis associated with NSCLC (\> 1 teaspoon in a single episode within 4 weeks)
Patients with any one of the following:
Patients with long QT syndrome
Patients with a Baseline 12-lead ECG QTc of \> 450 msec per central evaluation
Congestive heart failure (NY Heart Association class III or IV)
Patients with a myocardial infarction within 12 months of study entry
Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris
History of labile hypertension or poor compliance with anti-hypertensive regimen
History of a sustained ventricular tachycardia
Any history of ventricular fibrillation or Torsades de Pointes
Right bundle branch block and left anterior hemiblock (bifasicular block)
Bradycardia defined as heart rate \< 50 beats per minute
Concomitant use of drugs with a risk of causing Torsades de Pointes (See Table 6-3)
Known allergy or hypersensitivity to platinum-containing drugs, taxanes, other drugs formulated in Cremophor EL (polyoxyethylated castor oil) or any known excipients of these drugs.
Peripheral sensory neuropathy with functional impairment (CTC grade 2 neuropathy, regardless of causality)
Pregnant or breast feeding females
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/ml)
Women of child bearing potential or sexually active males, unwilling or unable to use the required highly effective method(s) of contraception for both sexes while receiving treatment and for at least 6 months after the discontinuation of study treatment. (Adequate forms of contraception include IUD, oral or depot contraceptive or the barrier method plus spermicide.)
• Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions while taking paclitaxel and therefore are not considered effective contraceptive methods for this study when used as a single agent. Therefore, it is highly recommended that a concomitant barrier method be used with oral, implantable, or injectable contraceptives. The investigator shall counsel the patient accordingly. Women of childbearing potential must have a negative pregnancy test (serum or urine) 72 hours prior to administration of study treatment. For a list of substrates of human liver microsomal P450 enzymes, visit website (http://medicine.iupui.edu/flockhart/)
Concurrent severe and/or uncontrolled medical disease (i.e. uncontrolled diabetes, chronic renal disease, chronic liver disease, confirmed diagnosis of HIV infection or active uncontrolled infection).
Significant neurologic or psychiatric disorder which could compromise participation in the study Patient unwilling or unable to comply with the protocol

Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico de ASA404 en combinación con Paclitaxel y carboplatin como tratamiento de primera línea para el cáncer de pulmón de células no pequeñas (CPCNP) localmente avanzado o metastásico (estadio IIIb/IV)

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

ASA404

Placebo

carboplatin

Paclitaxel

Ubicaciones

Novartis Investigative Site

Novartis Investigative Site

Novartis Investigative Site

Novartis Investigative Site

Novartis Investigative Site

Novartis Investigative Site

Patrocinadores